vs
CareDx, Inc.（CDNA）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
RESOURCES CONNECTION, INC.的季度营收约是CareDx, Inc.的1.0倍（$117.7M vs $117.7M），CareDx, Inc.净利率更高（2.4% vs -10.8%，领先13.1%），CareDx, Inc.同比增速更快（39.0% vs -19.2%），RESOURCES CONNECTION, INC.自由现金流更多（$15.6M vs $514.0K），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs -11.8%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
CDNA vs RGP — 直观对比
营收规模更大
RGP
是对方的1.0倍
$117.7M
营收增速更快
CDNA
高出58.1%
-19.2%
净利率更高
CDNA
高出13.1%
-10.8%
自由现金流更多
RGP
多$15.1M
$514.0K
两年增速更快
CDNA
近两年复合增速
-11.8%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $117.7M |
| 净利润 | $2.8M | $-12.7M |
| 毛利率 | — | 37.1% |
| 营业利润率 | 1.0% | -10.3% |
| 净利率 | 2.4% | -10.8% |
| 营收同比 | 39.0% | -19.2% |
| 净利润同比 | — | 81.6% |
| 每股收益（稀释后） | $0.05 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARGP
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $117.7M | ||
| Q3 25 | $100.1M | $120.2M | ||
| Q2 25 | $86.7M | $139.3M | ||
| Q1 25 | $84.7M | $129.4M | ||
| Q4 24 | $86.6M | $145.6M | ||
| Q3 24 | $82.9M | $136.9M | ||
| Q2 24 | $92.3M | $148.2M |
净利润CDNARGP
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $-12.7M | ||
| Q3 25 | $1.7M | $-2.4M | ||
| Q2 25 | $-8.6M | $-73.3M | ||
| Q1 25 | $-10.4M | $-44.1M | ||
| Q4 24 | $87.7M | $-68.7M | ||
| Q3 24 | $-10.6M | $-5.7M | ||
| Q2 24 | $-4.6M | $10.5M |
毛利率CDNARGP
| Q1 26 | — | — | ||
| Q4 25 | — | 37.1% | ||
| Q3 25 | — | 39.5% | ||
| Q2 25 | — | 40.2% | ||
| Q1 25 | — | 35.1% | ||
| Q4 24 | — | 38.5% | ||
| Q3 24 | — | 36.5% | ||
| Q2 24 | — | 40.2% |
营业利润率CDNARGP
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | -10.3% | ||
| Q3 25 | -0.2% | -1.7% | ||
| Q2 25 | -12.8% | -47.0% | ||
| Q1 25 | -15.8% | -38.4% | ||
| Q4 24 | 97.5% | -52.7% | ||
| Q3 24 | -16.6% | -3.5% | ||
| Q2 24 | -7.9% | 7.6% |
净利率CDNARGP
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | -10.8% | ||
| Q3 25 | 1.7% | -2.0% | ||
| Q2 25 | -9.9% | -52.6% | ||
| Q1 25 | -12.2% | -34.0% | ||
| Q4 24 | 101.3% | -47.2% | ||
| Q3 24 | -12.8% | -4.2% | ||
| Q2 24 | -5.0% | 7.1% |
每股收益（稀释后）CDNARGP
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $-0.38 | ||
| Q3 25 | $0.03 | $-0.07 | ||
| Q2 25 | $-0.16 | $-2.21 | ||
| Q1 25 | $-0.19 | $-1.34 | ||
| Q4 24 | $1.60 | $-2.08 | ||
| Q3 24 | $-0.20 | $-0.17 | ||
| Q2 24 | $-0.09 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $89.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $194.6M |
| 总资产 | $411.1M | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNARGP
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $89.8M | ||
| Q3 25 | $194.2M | $77.5M | ||
| Q2 25 | $186.3M | $86.1M | ||
| Q1 25 | $230.9M | $72.5M | ||
| Q4 24 | $260.7M | $78.2M | ||
| Q3 24 | $240.9M | $89.6M | ||
| Q2 24 | $228.9M | $108.9M |
总债务CDNARGP
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益CDNARGP
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $194.6M | ||
| Q3 25 | $311.1M | $206.4M | ||
| Q2 25 | $327.4M | $207.1M | ||
| Q1 25 | $379.3M | $277.8M | ||
| Q4 24 | $378.4M | $325.7M | ||
| Q3 24 | $273.2M | $407.2M | ||
| Q2 24 | $264.7M | $418.8M |
总资产CDNARGP
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $289.3M | ||
| Q3 25 | $432.3M | $287.2M | ||
| Q2 25 | $444.3M | $304.7M | ||
| Q1 25 | $489.6M | $375.6M | ||
| Q4 24 | $491.1M | $424.9M | ||
| Q3 24 | $477.0M | $512.9M | ||
| Q2 24 | $466.8M | $510.9M |
负债/权益比CDNARGP
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $15.6M |
| 自由现金流率自由现金流/营收 | 0.4% | 13.2% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $24.3M |
8季度趋势，按日历期对齐
经营现金流CDNARGP
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $15.9M | ||
| Q3 25 | $37.4M | $-7.8M | ||
| Q2 25 | $9.9M | $16.8M | ||
| Q1 25 | $-26.6M | $659.0K | ||
| Q4 24 | $21.9M | $1.8M | ||
| Q3 24 | $12.5M | $-309.0K | ||
| Q2 24 | $18.9M | $3.2M |
自由现金流CDNARGP
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $15.6M | ||
| Q3 25 | — | $-8.0M | ||
| Q2 25 | — | $16.5M | ||
| Q1 25 | — | $238.0K | ||
| Q4 24 | — | $61.0K | ||
| Q3 24 | — | $-575.0K | ||
| Q2 24 | — | $3.0M |
自由现金流率CDNARGP
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | 13.2% | ||
| Q3 25 | — | -6.6% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | -0.4% | ||
| Q2 24 | — | 2.1% |
资本支出强度CDNARGP
| Q1 26 | — | — | ||
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.1% |
现金转化率CDNARGP
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.30× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
